Here’s a practical side‑by‑side on phenytoin vs levetiracetam (levetiracetam sold as Keppra):
Key differences
- Mechanism and spectrum
- Phenytoin: stabilizes neuronal membranes by blocking voltage-gated sodium channels; mainly used for focal seizures and some generalized tonic–clonic seizures.
- Levetiracetam: binds to the SV2A vesicle protein; broad‑spectrum but exact mechanism not fully understood.
- Pharmacokinetics
- Phenytoin: nonlinear (saturable) hepatic metabolism; highly protein bound; autoinduction can change levels; many drug–drug interactions.
- Levetiracetam: linear kinetics; not significantly protein bound; primarily renally excreted; minimal hepatic metabolism; few drug interactions.
- Dosing and monitoring
- Phenytoin: dosing is complex; needs trough level monitoring (total phenytoin 10–20 mcg/mL, free levels if albumin is abnormal). Loading and maintenance doses can be tricky due to nonlinearity.
- Levetiracetam: simpler dosing; often starts at ~500 mg twice daily (adjust up to ~3 g/day in adults; renal dosing adjustments needed). Routine drug-level monitoring is not usually required.
- Drug interactions
- Phenytoin: many interactions (warfarin, oral contraceptives, other AEDs, etc.) because it induces multiple liver enzymes.
- Levetiracetam: minimal clinically relevant drug interactions; changes in mood or behavior can occur in some patients and should be monitored.
- Side effects and safety
- Phenytoin: dizziness, ataxia, nystagmus; gum hyperplasia, hirsutism; rash (including Stevens–Johnson in rare cases); osteoporosis with long-term use; teratogenic and can cause fetal malformations.
- Levetiracetam: somnolence, dizziness, fatigue; behavioral changes (irritability, agitation, mood worsening) in some people; rash is rare; suicidality risk is a class concern for AEDs.
- Pregnancy considerations
- Phenytoin: known teratogen with risks like neural tube defects and fetal hydantoin syndrome.
- Levetiracetam: generally considered to have a more favorable safety profile in pregnancy, but not risk-free; decisions are individualized with a clinician.
- Administration routes and status epilepticus
- Both are available in oral and IV forms.
- Phenytoin (often as fosphenytoin IV) has infusion rate limits and requires saline compatibility; IV phenytoin can cause cardiac or infusion‑related issues.
- Levetiracetam IV is typically easier to administer, with fewer infusion concerns.
- Cost and real-world use
- Levetiracetam is usually more expensive and is widely used as a first‑line option because of its safety and tolerability.
- Phenytoin is inexpensive but requires careful monitoring and has many interactions; still used in certain settings and when cost is a major factor or when patients have a specific response profile.
When to consider one over the other
- Levetiracetam is often preferred when:
- You want minimal drug interactions and straightforward dosing.
- The patient has complex polypharmacy, liver disease, or pregnancy considerations.
- You need a predictable option for initial therapy or for broader seizure control.
- IV therapy is needed (easier to manage, with fewer infusion issues).
- Phenytoin might be chosen when:
- Cost is a major constraint and the patient can be monitored closely for interactions and side effects.
- There is a history of good response and tolerability, or specific clinical scenarios where phenytoin is preferred.
- In some status epilepticus protocols, phenytoin (or fosphenytoin) is used as an alternative to levetiracetam after benzodiazepines.
Practical takeaways
- For most adult patients starting a new antiseizure regimen, levetiracetam is often favored due to safety, tolerability, and simplicity.
- If you are considering phenytoin, be prepared for more monitoring (drug levels, liver function, CBC), potential interactions, and dosing complexity.
- In status epilepticus, both can be used IV after benzodiazepines, but dosing and protocol specifics differ; local guidelines usually provide exact dosing.
- Always individualize based on age, pregnancy plans, comorbidities (especially liver and kidney function), concurrent medications, and access/cost considerations.
If you have a specific patient profile (age, sex, pregnancy plan, liver/kidney function, other meds, prior seizure types), I can tailor a more precise comparison and suggest likely dosing ranges and monitoring plans.